Aleve data vs. Advil shows "trend" toward longer action, court says in rejecting AHP suit.
This article was originally published in The Tan Sheet
Executive Summary
ALEVE CLINICAL DATA VS. ADVIL SHOWS "TREND" TOWARD LONGER ACTION, U.S. District Court Judge Nicholas Politan said Dec. 27 in deny-ing American Home Products' request for a preliminary injunction against Procter-Syntex. Politan stated that "it is patent" from evaluating three studies comparing the pain relief duration of naproxen sodium and ibuprofen with placebo over a 12-hour period that the "consistent trends of all three studies strongly suggest that naproxen sodium, that is, Aleve, has a longer duration and is more efficacious at the later hours (i.e., hours 8 through 12) than Advil."
You may also be interested in...
Aleve Challenge, New Study Catch Up To Advil 'Works Longer' Claim In NAD Review
Although 1993 studies to make Aleve available OTC didn't support claiming the naproxen oral analgesic lasted longer than ibuprofen-containing Advil, 2018 study Bayer submitted for National Advertising Division review shows Advil's efficacy doesn't exceed Aleve's. Report also says while Pfizer criticized inpatient methodology of Bayer's study, inpatient is industry standard method for pain medication trials.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands